Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study

详细信息    查看全文

• 作者：M Kay Garcia ; Lorenzo Cohen ; Ying Guo ; Yuhong Zhou…
• 关键词：Acupuncture ; Myeloma ; Chemotherapy ; Peripheral neuropathy ; Integrative medicine
• 刊名：Journal of Hematology & Oncology
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：7
• 期：1
• 全文大小：251 KB
• 参考文献：1. Richardson, PG, Delforge, M, Beksac, M, Wen, P, Jongen, JL, Sezer, O, Terpos, E, Munshi, N, Palumbo, A, Rajkumar, SV, Harousseau, JL, Moreau, P, Avet-Loiseau, H, Lee, JH, Cavo, M, Merlini, G, Voorhees, P, Chng, WJ, Mazumder, A, Usmani, S, Einsele, H, Comenzo, R, Orlowski, R, Vesole, D, Lahuerta, JJ, Niesvizky, R, Siegel, D, Mateos, MV, Dimopoulos, M, Lonial, S (2012) Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia 26: pp. 595-608 CrossRef
  2. Richardson, PG, Weller, E, Lonial, S, Jakubowiak, AJ, Jagannath, S, Raje, NS, Avigan, DE, Xie, W, Ghobrial, IM, Schlossman, RL, Mazumder, A, Munshi, NC, Vesole, DH, Joyce, R, Kaufman, JL, Doss, D, Warren, DL, Lunde, LE, Kaster, S, Delaney, C, Hideshima, T, Mitsiades, CS, Knight, R, Esseltine, DL, Anderson, KC (2010) Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116: pp. 679-686 CrossRef
  3. Velasco, R, Petit, J, Clapes, V, Verdu, E, Navarro, X, Bruna, J (2010) Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients. J Peripher Nerv Syst 15: pp. 17-25 CrossRef
  4. Raab, MS, Podar, K, Breitkreutz, I, Richardson, PG, Anderson, KC (2009) Multiple myeloma. Lancet 374: pp. 324-339 CrossRef
  5. Kaufmann, H, Raderer, M, Wohrer, S, Puspok, A, Bankier, A, Zielinski, C, Chott, A, Drach, J (2004) Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 104: pp. 2269-2271 CrossRef
  6. Cavo, M, Pantani, L, Petrucci, MT, Patriarca, F, Zamagni, E, Donnarumma, D, Crippa, C, Boccadoro, M, Perrone, G, Falcone, A, Nozzoli, C, Zambello, R, Masini, L, Furlan, A, Brioli, A, Derudas, D, Ballanti, S, Dessanti, ML, De Stefano, V, Carella, AM, Marcatti, M, Nozza, A, Ferrara, F, Callea, V, Califano, C, Pezzi, A, Baraldi, A, Grasso, M, Musto, P, Palumbo, A (2012) Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood 120: pp. 9-19 CrossRef
  7. Umapathi, T, Chaudhry, V (2005) Toxic neuropathy. Curr Opin Neurol 18: pp. 574-580 CrossRef
  8. Argyriou, AA, Bruna, J, Marmiroli, P, Cavaletti, G (2012) Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol 82: pp. 51-77 CrossRef
  9. Grisold, W, Cavaletti, G, Windebank, AJ (2012) Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol 14: pp. iv45-iv54 CrossRef
  10. Argyriou, AA, Iconomou, G, Kalofonos, HP (2008) Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 112: pp. 1593-1599 CrossRef
  11. Johnson, DC, Corthals, SL, Walker, BA, Ross, FM, Gregory, WM, Dickens, NJ, Lokhorst, HM, Goldschmidt, H, Davies, FE, Durie, BG, Van Ness, B, Child, JA, Sonneveld, P, Morgan, GJ (2011) Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol 29: pp. 797-804 CrossRef
  12. Lao, L, Hamilton, GR, Fu, J, Berman, BM (2003) Is acupuncture safe? A systematic review of case reports. Altern Ther Health Med 9: pp. 72-83
  13. Ernst, E, White, AR (2001) Prospective studies of the safety of acupuncture: a systematic review. Am J Med 110: pp. 481-485 CrossRef
  14.
• 刊物主题：Oncology; Hematology; Cancer Research;
• 出版者：BioMed Central
• ISSN：1756-8722

文摘

Background This single-arm study evaluated feasibility, safety, and initial efficacy of electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy (PN) in cancer patients with multiple myeloma. Methods Patients with neuropathy?≥?grade 2 received 20 acupuncture treatments over 9?weeks. Results For the 19 evaluable patients, Functional Assessment of Cancer Therapy/Gynecological Oncology Group-Neurotoxicity (FACT/GOG/NTX) mean (SD) scores improved significantly between baseline and week 13 (20.8 [9.6] vs 13.2 [8.5], p--.0002). Moderate effect size differences began on week 4, with the largest effect size differences found at week 9 for FACT/GOG/NTX scores, worst pain in the last 24?hours, and pain severity (Cohen’s d--.43, 1.19, and 1.08, respectively) and continuing through week 13 (Cohen’s d--.86, 0.88, and 0.90, respectively). From baseline to week 13, additional significant improvements were seen as follows: postural stability (1.0 [0.6] vs 0.8 [0.4], p--.02); coin test (10.0 [7.4] vs 5.6 [1.9], p--.0001); button test (96.1 [144.4] vs 54.9 [47.3], p--.0001); and walking test (21.6 [10.0] vs 17.2 [7.7], p--.0003). No significant changes were seen with NCS. Conclusions Acupuncture may help patients experiencing thalidomide- or bortezomib-induced PN. Larger, randomized, clinical trials are needed. Trial registration ClinicalTrials.gov Identifier: NCT00891618.